Alnylam Reports Positive Clinical Results â with up to 94% Knockdown of Serum Transthyretin (TTR) â for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis (ATTR)